 |
|
Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Byoung Soo Kwon, Ji Hyun Park, Woo Sung Kim, Joon Seon Song, Chang-Min Choi, Jin Kyung Rho, Jae Cheol Lee
Tuberc Respir Dis. 2017;80(2):187-193. Published online 2017 Mar 31 DOI: https://doi.org/10.4046/trd.2017.80.2.187
|
|
Citations to this article as recorded by
 EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
Journal of Personalized Medicine.2024; 14(7): 752. CrossRef New Targeted Therapy for Non-Small Cell Lung Cancer
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee
Tuberculosis and Respiratory Diseases.2023; 86(1): 1. CrossRef Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis
Yong Dong, Qijun Li, Qian Miao, Da Li
Medicine.2021; 100(25): e26450. CrossRef Expression and copy number gains of the RET gene in 631 early and mid stage non‐small cell lung cancer cases
Ling Tan, Yerong Hu, Yongguang Tao, Bin Wang, Jun Xiao, Zhenjie Tang, Ting Lu, Hao Tang
Thoracic Cancer.2018; 9(4): 445. CrossRef
|